Secondary myelodysplastic syndrome (sMDS) and acute myelogenous leukemia (AML) have been recognized with increasing frequency following autologous stem cell transplantation (ASCT). A retrospective analysis of 230 consecutive patients with Hodgkin's lymphoma (HL, 64) and non-Hodgkin's lymphoma (NHL, 166) who underwent ASCT was conducted to assess the incidence and risk factors for the development of sMDS/AML. At a median follow up of 41 months (range 0.1-177 months), 10 of 230 patients (4.3%) developed sMDS/AML. The 5-yearactuarial incidence of sMDS/AML was 13.1% and 5-year cumulative incidence by competing risk analysis was 4.2%. The median time to development of sMDS/AML was 39.9 months from the time of ASCT (range 12.1-62.0 months). Complex karyotypes at diagnosis of sMDS/ AML included structural anomalies and/or loss of chromosome 5 (eight patients), 7 (five patients), 17 (two patients) and 20 (two patients). All patients subsequently died, at a median of 6.8 months (range 0-39.9) from diagnosis of sMDS/AML. Fluorescent in situ hybridization (FISH) analysis for À5/5q-and À7/7q-were normal in all six patients whose pre-ASCT bone marrow was available for testing. Five of the six had samples available for testing at diagnosis of sMDS/AML and all had abnormal FISH results. By univariate statistical analysis, male gender (P ¼ 0.01), prior alkylating agents (mechlorethamine for HL, P ¼ 0.001 and cyclophosphamide for NHL, P ¼ 0.05) and the number of prior treatment regimens (P ¼ 0.04) were significantly associated with the development of sMDS/AML. Given the relatively low incidence rate of sMDS/AML, these analyses are primarily exploratory in nature but provide some insight into relevant risk factors and illustrate the risk of developing sMDS/AML after myeloablative conditioning and ASCT for lymphoma.
Summary:
Secondary myelodysplastic syndrome (sMDS) and acute myelogenous leukemia (AML) have been recognized with increasing frequency following autologous stem cell transplantation (ASCT). A retrospective analysis of 230 consecutive patients with Hodgkin's lymphoma (HL, 64) and non-Hodgkin's lymphoma (NHL, 166) who underwent ASCT was conducted to assess the incidence and risk factors for the development of sMDS/AML. At a median follow up of 41 months (range 0.1-177 months), 10 of 230 patients (4.3%) developed sMDS/AML. The 5-yearactuarial incidence of sMDS/AML was 13.1% and 5-year cumulative incidence by competing risk analysis was 4.2%. The median time to development of sMDS/AML was 39.9 months from the time of ASCT (range 12.1-62.0 months). Complex karyotypes at diagnosis of sMDS/ AML included structural anomalies and/or loss of chromosome 5 (eight patients), 7 (five patients), 17 (two patients) and 20 (two patients). All patients subsequently died, at a median of 6.8 months (range 0-39.9) from diagnosis of sMDS/AML. Fluorescent in situ hybridization (FISH) analysis for À5/5q-and À7/7q-were normal in all six patients whose pre-ASCT bone marrow was available for testing. Five of the six had samples available for testing at diagnosis of sMDS/AML and all had abnormal FISH results. By univariate statistical analysis, male gender (P ¼ 0.01), prior alkylating agents (mechlorethamine for HL, P ¼ 0.001 and cyclophosphamide for NHL, P ¼ 0.05) and the number of prior treatment regimens (P ¼ 0.04) were significantly associated with the development of sMDS/AML. Given the relatively low incidence rate of sMDS/AML, these analyses are primarily exploratory in nature but provide some insight into relevant risk factors and illustrate the risk of developing sMDS/AML after myeloablative conditioning and ASCT for lymphoma. Bone Marrow Transplantation (2003) 32, 317-324. doi:10.1038/sj.bmt.1704124 Keywords: secondary MDS; autologous stem cell transplantation; lymphoma Autologous stem cell transplantation (ASCT) is an increasingly important therapy for patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Long-term disease-free survival rates post ASCT now approach 50% or more in some settings, and these patients may be cured of their lymphoma. [1] [2] [3] Although recurrence of disease remains the major cause of failure following ASCT with relapse rates approaching 40%, secondary myelodysplastic syndrome (sMDS) and acute myelogenous leukemia (AML) have been recognized with increasing frequency post ASCT and are usually fatal. [4] [5] [6] [7] [8] The 5-year actuarial incidence rates of approximately 3-18% have been previously reported. 6, [9] [10] [11] [12] [13] [14] [15] Factors shown to be associated with the development of sMDS and AML include older age, 9, 13, 14, 16 amount and type of chemotherapy received prior to transplantation, 9, 11, 12, 15, [17] [18] [19] [20] length of time between diagnosis of lymphoma and transplantation, 11 prior radiation therapy, 11, 15 chemotherapy utilized for peripheral blood stem cell mobilization, 20 number, 21 and source 5, 10, 22, 23 of stem cells reinfused and the use of total body irradiation as part of the conditioning regimen. 7, 14, 16, 24 The primary goals of this study were to assess the frequency of sMDS/AML post ASCT in patients with HL and NHL at Mayo Clinic Rochester, to further define possible risk factors for sMDS/AML that may predispose patients to developing this complication, and to describe the cytogenetic and FISH results on the bone marrow (BM) samples pre-ASCT and post-ASCT at diagnosis of sMDS/ AML.
Patients and methods

Patients
The study population consisted of 230 consecutive patients with HL (64) or NHL (166) who underwent high-dose therapy with ASCT at Mayo Clinic Rochester, between April 1985 and December 1998, with follow-up through July 2002. Three patients received two transplants. One patient was initially diagnosed with HL, underwent ASCT 13 years later for relapsed disease and achieved a complete remission. At 18 months following the first ASCT, he relapsed with NHL and received a second ASCT; 2 months later, he developed AML. For the current study, this patient was classified with a diagnosis of HL. The other two patients who underwent second ASCT for disease relapse did not develop sMDS or AML. The data for each of these three patients are presented with respect to the first transplant only.
BM and peripheral blood stem cell collection BM was harvested under general anesthesia. Peripheral blood stem cells (PBSC) were harvested after G-CSF priming. CD34 quantitation was routinely performed starting in May 1997, using the standard method of ProCount by Becton Dickinson. No in vitro manipulation of the PBSC or BM harvests was done. Cells were cryopreserved and thawed immediately prior to use. Pretransplant cytogenetic analysis by G-banding was performed on BM specimens obtained as part of the pretransplant testing and all were negative for chromosome abnormalities. Patients with abnormal karyotypes were excluded from transplantation. /day Â 3 days)); and 58 patients received CyTBI (cyclophosphamide (60 mg/kg/day Â 2 days) and total body irradiation (1320 cGy in 6 fractions)). Additional protocols included: 6-thioguanine/VP-16/ BCNU/Ara-C/total body irradiation (two patients), busulfan/cyclophosphamide (one patient), VP-16/thiotepa/cyclophosphamide (one patient).
Hospitalization and follow-up
Patients were treated in the Blood and Marrow Transplant Unit at Rochester Methodist Hospital, Mayo Clinic, Rochester MN, USA. All patients received standard supportive care as per guidelines in place at the time. Patients received G-CSF or GM-CSF post transplant to facilitate neutrophil engraftment. Patients were followed daily until adequate engraftment and until they were well enough to be discharged home. Routine reassessment was done at day 100 and then yearly at Mayo Clinic. Reassessment included CBC, routine chemistry profile and CT scans. BM analysis was left to the discretion of the transplant physician. After day 100, patients returned to their primary hematologist for ongoing assessment; however, yearly follow-up at Mayo Clinic Rochester was continued indefinitely. Those who developed second malignancies were identified either at Mayo Clinic or by their referring physician. No patients were lost to follow-up.
Diagnosis of sMDS and AML
World Health Organization (WHO) criteria were used in diagnosing sMDS and AML. 25 All BM samples and blood specimens were reviewed by a hematopathologist at Mayo Clinic, Rochester. Cytogenetic analysis was performed using standard G-banding techniques. 26 Abnormal clones were described using International System for Human Cytogenetic Nomenclature criteria. 27 Fluorescent in situ hybridization (FISH) analysis FISH analysis for À5 and/or 5qÀ (with probes for EGR1/ D5S23/D5S721 from Vysis, Inc., Downers Grove, IL, USA) and, À7 and/or 7qÀ (with probes for D7S522/ D7Z1 from Vysis Inc., Downers Grove, IL) was performed on patients BM cells pre-ASCT in six patients and in five of the six patients, at diagnosis of sMDS/AML. In all, 200 interphase nuclei per patient were scored by two independent observers to establish the percent abnormal cells. Prior to this study, the cutoff for normal values was calculated from 20 known normal specimens, using the upper bound of a one-sided 95% confidence interval for observing the maximum false-positive nuclei for each signal pattern observed in a single specimen using the binomial distribution. The normal cutoff for 5qÀ, À5, 7qÀ and -7 were 6.0, 4.0, 6.5 and 4.5%, respectively.
Data analysis
The primary end point of this study was the incidence of sMDS/AML in post-ASCT lymphoma patients. The variables analyzed as potential risk factors associated with the development of sMDS/AML included gender, age at ASCT, lymphoma histological diagnosis (HL vs NHL), prior radiation therapy, prior chemotherapy, prior splenectomy, conditioning regimen (TBI vs non-TBI), platelet count prior to ASCT, time from lymphoma diagnosis to ASCT, stem cell source (BM vs peripheral blood) and the number of stem cells re-infused as measured by mononuclear cells/kg. Since CD34 counting was not routinely performed until May 1997, it was available in only 41 patients (sMDS/AML n ¼ 2; non-MDS n ¼ 39) and therefore it was not included in the statistical analysis. Patients with NHL were analyzed as a single group, as well as divided into histological subgroups by Working Formulation 28 (low-grade NHL vs intermediate grade vs other (including angiocentric/angioblastic lymphoma, anaplastic large cell, precursor B and T cell immunoblastic, CNS T cell lymphoma, lymphoblastic T cell, cutaneous T cell, NK/T cell lymphoma)). In all, 15 of the 47 low-grade NHL subsequently transformed to more aggressive histological grades, but were analyzed in the 'low-grade' NHL group. Patients with HL were analyzed only as a single group because 56 of the 64 patients had Nodular Sclerosis HL.
Estimates of the exposure of patients to a given therapeutic agent were determined by summing the total number of cycles the patient received even when the regimen doses differed. In all, 19 of the patients who did not develop sMDS/AML had ambiguities in the total number of cycles given, and were not included in the univariate analyses shown here. This exclusion probably did not bias the results because these patients were few in number relative to the entire cohort (19 of 220 non-MDS patients), and when these 19 patients were included using estimates of the chemotherapy they received, statistical analysis was unchanged. The number of stem cells reinfused was reported separately based on source (PB vs BM). Presence or absence of growth factor treatment was not evaluated as a risk factor, since it is routine practice for all patients to receive either G-CSF or GM-CSF following ASCT to facilitate neutrophil engraftment.
Comparisons of categorical variables between those who did and did not develop sMDS/AML were done using Fisher's exact test. Comparisons of continuous variables between these groups were conducted using two-tailed, two-sample t-tests or the nonparametric equivalent (Wilcoxon rank-sum test). The associations of these variables with the incidence of sMDS/AML were also explored using logistic regression models. In addition to examining the incidence of sMDS/AML, we also summarized and evaluated the time from transplant to the development of sMDS/AML. The cumulative incidence of sMDS/AML was calculated using competing risk analysis, where death was considered the competing risk. Patients who relapsed were still considered to be at risk for sMDS/AML; therefore, relapse was not considered a competing risk. Despite the potential for bias, the actuarial incidence rate of patients with sMDS/AML was calculated using the reverse Kaplan-Meier estimate. 29 This was done primarily to compare the results from this study to those previously reported.
Several factors were analyzed and statistical significance was determined if the P-value was p0.05. Given the exploratory nature of these analyses, multiple comparison corrections were not used.
Results
Characteristics of secondary sMDS/AML or AML patients
Of the 230 patients who underwent high-dose chemotherapy and ASCT, 10 patients have developed sMDS or AML. The crude incidence rate of sMDS/AML was 4.3% (10/230). At the time of these analyses, 97 patients were alive, with a median follow-up of 69 months (range 36-177 months). Of the 10 patients who developed sMDS/ AML, all have since died. The 5-year actuarial incidence rate was 13.1% and the 5-year cumulative incidence rate was 4.3%, as determined by competing risk analysis ( Figure 1 ).
Baseline clinical characteristics and details of the diagnosis for the 10 patients who developed sMDS/AML are depicted in Table 1 . Median age at ASCT was 49 years (range 23-73). The median time from diagnosis to transplant was 35 months (range 15-151). Four patients received stem cells from BM and six from peripheral blood. Five patients had a prior diagnosis of NHL and five had HL. The median number of prior chemotherapy regimens prior to ASCT was 3 (range 2-4). All but one patients were in complete remission of lymphoma at the time of sMDS/ AML diagnosis. The histological diagnoses of sMDS included: refractory cytopenia with multilineage dysplasia (RCMD) in four patients, atypical MDS with fibrosis in two patients and refractory anemia with excess blasts (RAEB) in two patients. One patient with RCMD subsequently developed AML-M4. Two patients developed AML without an antecedent history of sMDS. The median time to development of sMDS/AML was 40 months (range 12-63 months) following ASCT and a median of 75 months (range 36-192 months) from original lymphoma diagnosis. All 10 patients died, where the time from diagnosis of sMDS/AML to death ranged from 0.5 to 40 months (median 7 months). Treatment of sMDS/AML included an allogeneic transplant in one patient and supportive care in the remainder. Cytogenetic analysis at diagnosis of sMDS/ AML was available in eight of 10 patients; all eight patients had at least three chromosome aberrations and four patients had X5 chromosome aberrations. Structural or numeric anomalies of chromosome five and seven were seen in eight and five patients, respectively. No patients had abnormalities of 11q23 or 21q22.
FISH analysis
BM samples from six patients, pre-ASCT had no evidence of abnormal clones by conventional cytogenetics or RT, Radiotherapy; LPHL, Lymphocyte predominant Hodgkin's lymphoma; NSHL, nodular sclerosing Hodgkin's lymphoma; DLCL, diffuse large-cell lymphoma, MCL, mantle cell lymphoma; SLL, small lymphocytic lymphoma; NHL, non-Hodgkin's lymphoma, MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; AML, acute myelogenous leukemia; RCMD, refractory cytopenia with multilineage dysplasia, Cy/TBI, cyclophophamide/total body irradiation; CBV, BCNU/cyclophosphamide/VP-16; BEAC, BCNU/cyclophosphamide/cytosine arabinoside/VP-16; ASCT, autologous stem cell transplant; BM, bone marrow; PBSC, peripheral blood stem cell; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; MOPP, mechlorethamine/vincristine/prednisone/procarbazine; ABVD, doxorubicin/bleomycin/vinblastine/dacarbazine; DHAP, dexamethasone/cytosine arabinoside (high dose)/cisplatin; ProMACE-CytaBOM, cyclophosphamide/doxorubicin/etoposide/prednisone/cytarabine/ bleomycin/methotrexate/vincristine; CEPP, cyclophosphamide/etoposide/procarbazine/prednisone; MOP-ABV, mechlorethamine/vincristine/procarbazine/doxorubicin/vinblastine/bleomycin; CHEP, cyclophosphamide/doxorubicin/etoposide/prednisone, mos, months; N/A, not available. a The Number in brackets, following each chemotherapy regimen, corresponds to the number of chemotherapy cycles the patient received.
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FISH studies. Five of the six patients tested pre-ASCT had BM samples that were available for testing at the time of diagnosis of sMDS/AML and all five were abnormal by conventional cytogenetic and FISH studies (Table 3) . To further define which drug might contribute to the increased risk associated with prior chemotherapy, we determined the total number of cycles given of each chemotherapeutic agent. We focused in particular on Table 2 Clinical characteristics of all patients undergoing ASCT Secondary MDS/AML R Howe et al alkylating agents and etoposide. 6, 23 Of the 64 patients with HL, all five who developed sMDS/AML, and 48 of the 59 who did not develop sMDS/AML received mechlorethamine, as present in MOPP. The number of cycles of mechlorethamine was significantly higher in HL patients developing sMDS/AML (median 14, range 6-18) compared to HL patients without sMDS/AML (median 6, range 0-12, P ¼ 0.001). In contrast, there were no significant differences in the number of procarbazine or cisplatin cycles between those HL patients who developed sMDS/AML and those without sMDS/AML (data not shown).
Risk factors for development of sMDS or AML
Among patients with NHL, all five who developed sMDS/AML and 160 of the 161 who did not develop sMDS/AML received cyclophosphamide. The number of cyclophosphamide cycles was higher in patients developing sMDS/AML (median 11, range 6-13) than among those without sMDS/AML (median 8, range 0-23, P ¼ 0.05). No significant differences were observed in the total number of etoposide or cisplatin cycles received between the NHL patients who developed sMDS/AML and those without sMDS/AML. Fludarabine was used in too few patients to assess its influence.
Discussion
Secondary MDS/AML remain important complications post ASCT. In this retrospective series, the crude, 5-year actuarial and 5-year cumulative incidence rates of sMDS or AML were 4, 13, and 4%, respectively, with a median time to diagnosis of approximately 3 years after transplant. The 5-year actuarial incidence by Kaplan-Meier of 13% is within the range (3-18%) reported in other studies. 6, [9] [10] [11] [12] [13] [14] [15] [16] [18] [19] [20] [21] [22] [23] We have shown the incidence by both Kaplan-Meier actuarial incidence and by competing risk analysis since both of these methods have been used in prior reports. The Kaplan-Meier actuarial incidence overestimates the cumulative incidence as it does not take into account the competing risk of death in this patient group.
There appears as yet to be no consensus on which risk factors are important for the development of sMDS/AML, but exposure to prior chemotherapy has been a consistent finding. 9, 11, 12, 18, 20, 24 This was confirmed in a recent large multicenter case-control study by Metayer et al 24 who identified type and intensity of pretransplant chemotherapy including mechlorethamine and chlorambucil as an important risk factor of sMDS/AML. There was also, an apparent association between sMDS/AML and high-dose TBI (413.2 Gy); however, this regimen was infrequently used and thus therefore needs to be confirmed. The data on TBI as a risk factor for sMDS/AML are conflicting. 14, 16, 24 We did not observe differences in the incidence of sMDS/ AML in patients who received TBI-containing conditioning regimens compared to non-TBI-containing conditioning regimens. Total chemotherapy cycles prior to transplant was significantly higher in those patients developing sMDS/ AML. In agreement with Metayer et al, 24 as well as others, 12, 30 we found that the total number of cycles of mechlorethamine in MOPP regimens prior to ASCT was significantly higher in HL patients with sMDS/AML. We also observed that among NHL patients, total prior cycles with cyclophosphamide was higher in sMDS/AML patients, although this finding only approached borderline statistical significance. Alkylator therapy is a known risk factor for sMDS/AML in the nontransplant setting; the 5-year estimated risk of sMDS/AML after long-term alkylator therapy or low-dose radiation is 7%. 31, 32 Secondary MDS/AML usually occurs in patients receiving longterm alkylator therapy such as continuous chlorambucil. The association of prior cyclophosphamide (pre-ASCT) with the incidence of sMDS/AML post ASCT has not been seen in other studies and therefore needs to be confirmed. Other factors including patient age, 9, 13, 14, 16 number, 21 or source 10, 13, 20, 23 of stem cells infused, pretransplant platelet levels 11 or splenectomy 23 have been observed in some, but not all studies. In this study, we did not see associations with sMDS/AML and any of these risk factors. Owing to the relatively low incidence rate of sMDS/AML, the nonsignificant results could potentially be because of a lack of power to detect all but very large differences in these variables between those who do and do not develop sMDS/ AML. Larger, confirmatory studies may be required to fully evaluate and determine significant risk factors for sMDS/AML.
One surprising result was that all patients who developed sMDS/AML were male. It is unclear why all the sMDS/ AML patients in this study were male. Conceivably, hormonal effects could influence hematopoiesis to enhance myelodysplasia or transformation in males, or inhibit this process in females. However, there have been no consistent prior associations of gender with development of sMDS or Normal cutoffs: À5=4.0%; 5qÀ=6.0%; À7=4.5%; 7qÀ=6.5%.
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AML, and this suggests that the association observed in this study may have been by chance alone. The consistent association in the literature between sMDS/AML and prior chemotherapy argues for pretransplant mutagenesis as at least one necessary event. This possibility is supported by the recent finding of multiple chromosome aberrations, by FISH analysis, present prior to transplantation in samples previously considered to be normal by less-sensitive techniques. [33] [34] [35] [36] In the study from St Bartholomew's Hospital, many of the aberrations found at diagnosis of sMDS/AML were detected pre-ASCT by FISH analysis, implying that a necessary event had already taken place prior to transplantation. 34 In contrast to these studies, we found no -5/5qÀ or -7/7qÀ abnormalities by either cytogenetic or FISH analysis among pretransplant samples from six of the patients. However, pretransplant samples from four of the patients were unavailable, and hence we may not be able to generalize these findings to all our patients with sMDS/AML. The equivalent sensitivity of conventional cytogenetics and FISH is similar to studies done in de novo MDS. Ketterling et al 37 tested 32 cytogenetically normal patients with primary MDS by FISH panel testing and by M-FISH. Only one of 32 patients had 13qÀ, while the remaining 31 were normal, suggesting limited utility in FISH testing over standard cytogenetics. Differences in FISH strategy and normal cutoff values may account for the discrepancy between the results in this present study and the previous reports. In addition, it is not clear whether mutational events, even when identified pre-ASCT, are both necessary and sufficient, or whether additional events are required post-ASCT for the development of sMDS/AML.
It is possible that secondary events, perhaps influencing proliferation or differentiation of a damaged clone, could contribute to tumorigenesis, for example, by impeding adaptive DNA repair mechanisms. Such secondary events could occur either prior to, at, or following transplantation. The fact that the time interval from transplant to sMDS/ AML is sometimes only a few months could be used as an argument against an obligatory post-transplant event. However, the median time to development of sMDS/ AML is usually in the range of 3-5 years, suggesting that it is at least somewhat related to the transplant itself. Several studies have implicated factors at the time of the transplant, such as total body irradiation, 14, 16, 24 use of etoposide for mobilization, 20 stem cell source, 10, 13, 20, 23 or number of stem cells transplanted (this study and 21 ) in the development of sMDS/AML. This could result in either new mutations or greater proliferative stress of previously damaged stem cells during transplantation. In contrast, a large cooperative study found that risk was virtually all associated with prior chemotherapy, and not with the transplant procedure, although patients were conditioned by BEAM and not TBI. 18 Given a likely multi-step mechanism for pathogenesis, as well as numerous patterns of chromosome aberrations in sMDS/AML, it is not surprising that there have been inconsistencies in risk factors associated with the development of sMDS/AML from study to study.
In summary, our results confirm the significant risk of developing either sMDS/AML following myeloablative conditioning and ASCT. It remains unclear whether pre-ASCT FISH analysis is more sensitive in detecting abnormal clones; thus, we are still unable to predict accurately which patients will develop this serious and usually fatal complication.
